Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials

M Dambrova, M Makrecka-Kuka, J Kuka… - Pharmacological …, 2022 - Elsevier
Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy
metabolism pathways. They have historically been used as important diagnostic markers for …

Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle

SJG Knottnerus, JC Bleeker, RCI Wüst… - Reviews in Endocrine …, 2018 - Springer
Mitochondrial fatty acid oxidation is an essential pathway for energy production, especially
during prolonged fasting and sub-maximal exercise. Long-chain fatty acids are the most …

[HTML][HTML] Fatty acid oxidation disorders

II J Lawrence Merritt, M Norris… - Annals of translational …, 2018 - ncbi.nlm.nih.gov
Fatty acid oxidation disorders (FAODs) are inborn errors of metabolism due to disruption of
either mitochondrial β-oxidation or the fatty acid transport using the carnitine transport …

Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies

M Wajner, AU Amaral - Bioscience reports, 2016 - portlandpress.com
Mitochondrial fatty acid oxidation (FAO) plays a pivotal role in maintaining body energy
homoeostasis mainly during catabolic states. Oxidation of fatty acids requires approximately …

Peroxisome-mitochondria interplay and disease

M Schrader, J Costello, LF Godinho… - Journal of inherited …, 2015 - Springer
Peroxisomes and mitochondria are ubiquitous, highly dynamic organelles with an oxidative
type of metabolism in eukaryotic cells. Over the years, substantial evidence has been …

Treatment recommendations in long‐chain fatty acid oxidation defects: consensus from a workshop

U Spiekerkoetter, M Lindner, R Santer… - Journal of Inherited …, 2009 - Wiley Online Library
Published data on treatment of fatty acid oxidation defects are scarce. Treatment
recommendations have been developed on the basis of observations in 75 patients with …

Long-term outcomes of individuals with metabolic diseases identified through newborn screening

U Mütze, SF Garbade, G Gramer, M Lindner… - …, 2020 - publications.aap.org
BACKGROUND: Although extended newborn screening (NBS) programs have been
introduced more than 20 years ago, their impact on the long-term clinical outcome of …

Nutrition in chronic liver disease: consensus statement of the Indian national association for study of the liver

P Puri, RK Dhiman, S Taneja, P Tandon, M Merli… - Journal of clinical and …, 2021 - Elsevier
Malnutrition and sarcopenia are common in patients with chronic liver disease and are
associated with increased risk of decompensation, infections, wait-list mortality and poorer …

Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency

K Yamada, T Taketani - Journal of human genetics, 2019 - nature.com
Mitochondrial fatty acid oxidation disorders (FAODs) are caused by defects in β-oxidation
enzymes, including very long-chain acyl-CoA dehydrogenase (VLCAD), trifunctional protein …

Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening

U Spiekerkoetter - Journal of inherited metabolic disease, 2010 - Springer
The different long-chain fatty acid oxidation defects present with similar heterogeneous
clinical phenotypes of different severity. Organs mainly affected comprise the heart, liver …